These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 19010207

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, Gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou G, Carratalà J, Torre-Cisneros J, Pahissa A, RESITRA.
    Clin Infect Dis; 2008 Jan 01; 46(1):20-7. PubMed ID: 18171208
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
    Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, Fields KK, Goldstein S.
    Bone Marrow Transplant; 2006 May 01; 37(9):851-6. PubMed ID: 16532016
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
    Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S, Palau J, Romero M, Montava A, Senent L, Martínez J, Jarque I, Salavert M, Córdoba J, Gómez L, Weiss S, Moscardó F, de la Rubia J, Larrea L, Sanz MA, Sanz GF.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):730-40. PubMed ID: 19450758
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M.
    Transpl Infect Dis; 2007 Jun 01; 9(2):102-7. PubMed ID: 17461994
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.
    Díaz-Pedroche C, Lumbreras C, Del Valle P, San Juan R, Hernando S, Folgueira D, Andrés A, Delgado J, Meneu JC, Morales JM, Moreno E, Aguado JM.
    Transplant Proc; 2005 Nov 01; 37(9):3766-7. PubMed ID: 16386532
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study.
    Park SY, Lee SO, Choi SH, Kim YS, Woo JH, Baek S, Sung H, Kim MN, Kim DY, Lee JH, Lee JH, Lee KH, Kim SH.
    J Antimicrob Chemother; 2012 Jun 01; 67(6):1486-92. PubMed ID: 22354954
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients.
    Palladino M, Laurenti L, Chiusolo P, Piccioni P, Innocenti I, Tarnani M, Sorà F, Sica S, Leone G.
    Acta Haematol; 2010 Jun 01; 123(4):230-4. PubMed ID: 20424437
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
    Mattes FM, Hainsworth EG, Hassan-Walker AF, Burroughs AK, Sweny P, Griffiths PD, Emery VC.
    J Infect Dis; 2005 Jan 01; 191(1):89-92. PubMed ID: 15593008
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
    Chawla JS, Ghobadi A, Mosley J, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R.
    Transpl Infect Dis; 2012 Jun 01; 14(3):259-67. PubMed ID: 22093134
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 01; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K, Basu A, Tan HP, Thai N, Khan A, Marcos A, Starzl TE, Shapiro R.
    Transplant Proc; 2004 Dec 01; 36(10):3107-12. PubMed ID: 15686707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.